Jump to content

Phillip D. Zamore

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Seekerojustice (talk | contribs) at 18:33, 30 October 2018 (added the). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Phillip D. Zamore, Ph.D., is an American molecular biologist and developed the first in vitro system for studying the mechanism of RNA interference (RNAi). He is the Gretchen Stone Cook Professor of Biomedical Sciences and Professor of Biochemistry and Molecular Pharmacology[1] at University of Massachusetts Medical School, located in Worcester, MA. Dr. Zamore is the Chair of the RNA Therapeutics Institute (RTI) at UMass Medical School, established in 2009, and has been a Howard Hughes Medical Institute Investigator since 2008[2].  

Research

The Zamore lab at the RTI focuses on understanding the underlying processes of RNAi; how small RNAs (miRNA, siRNA, piRNA) are involved in gene regulation networks[3]. In addition to a focus on basic research, the Zamore lab is working with Dr. Neil Aronin, MD, to develop siRNA-based drugs to treat Huntington’s disease (HD)[2]. Dr. Zamore has more than 40,000 citations on Google Scholar[4].

Biography

Dr. Zamore received his A.B. in Biochemistry and Molecular Biology from Harvard University in Cambridge, MA, in 1986 and continued graduate studies with Dr. Michael Green at Harvard, receiving his Ph.D. in 1992[1]. After completing postdoctoral studies The Whitehead Institute for Biomedical Research at MIT and the Skirball Institute at New York University Medical Center with Ruth Lehmann[1], Dr. Zamore began his academic career as an Assistant Professor in the Department of Biochemistry and Molecular Pharmacology in 1999 at UMass Medical School in Worcester, MA where he is now the Gretchen Stone Cook Professor of Biomedical Sciences and Professor of Biochemistry and Molecular Pharmacology.

Involvement with Biotechnology

Dr. Zamore’s research has led to a career in biotechnology, co-founding Alynlam Pharmaceuticals[5] in 2002. Alnylam is dedicated to bringing RNAi based therapies to market and developed the first-ever FDA approved RNAi drug, Patisiran, gaining FDA approval in August 2018[6]. Dr. Zamore currently sits on the scientific advisor board for Alnylam[7]. In 2014, Dr. Zamore co-founded another RNAi based company; Voyager Therapeutics[8], which focuses on developing therapeutics for neurodegenerative disorders.

Selected Awards and Honors

  1. Invented Here! Honoree, Boston Patent Law Association, for US patent US 9,226,976, “RAAV- Based Compositions and Methods for Treating Alpha-1 Anti-Trypsin Deficiencies,” October 2017
  2. Paper of the Year (Salomon et al., Cell 2015), Oligonucleotide Therapeutics Society[9]
  3. “The World’s Most Influential Scientific Minds 2014,” Molecular Biology & Genetics, Thomson-Reuters[10]
  4. Top 20 Translational Researchers of 2014, Nature Biotechnology[11]
  5. Fellow, National Academy of Inventors, December 2014[12]
  6. Outstanding Research Achievement, Nature Biotechnology SciCafé June 2009
  7. Schering-Plough Award, American Society of Biochemistry and Molecular Biology, April 2009
  8. Top 20 Most Highly Cited Researchers in Molecular Biology and Genetics, 2002–2006, ScienceWatch (Thomson Scientific)[2]
  9. Most Highly Cited Researchers, 2002–2012 (Thomson-Reuters)[1]
  10. Recipient, Chancellor’s Medal for Excellence in Scholarship, University of Massachusetts Medical School[13]

-----Note: this list is incomplete, for more information visit https://www.zamorelab.umassmed.edu/

Selected Publications

  • Hutvágner, G., McLachlan, J., Pasquinelli, A. E., Bálint, É., Tuschl, T., Zamore, P. D. (2001). A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293, 834-838. https://www.ncbi.nlm.nih.gov/pubmed/11452083
  • Hutvágner, G., and Zamore, P.D. (2002). A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056-2060. https://www.ncbi.nlm.nih.gov/pubmed/12154197
  • Schwarz, D.S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., Zamore, P.D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208. https://www.ncbi.nlm.nih.gov/pubmed/14567917
  • Tomari, Y., Du, T., Haley, B., Schwarz, D.S., Bennett, R. Cook, H.A., Koppetsch, B.S., Theurkauf, W.E., Zamore, P.D. (2004). RISC assembly defects in the Drosophila RNAi mutant armitage. Cell 116, 831-841. https://www.ncbi.nlm.nih.gov/pubmed/15035985
  • Vagin, V.V., Sigova, A., Li, C., Seitz, H., Gvozdev, V., Zamore, P.D. (2006). A distinct small RNA pathway silences selfish genetic elements in the germ line. Science 313, 320-324. https://www.ncbi.nlm.nih.gov/pubmed/16809489
  • Tomari, Y., Du, T., Zamore, P.D. (2007). Sorting of Drosophila small silencing RNAs. Cell 130, 299-308. (PMCID: PMC2841505). https://www.ncbi.nlm.nih.gov/pubmed/17662944
  • DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yodel, J., Reeves, P., Pandey, R.K., Rajeev, K.G., Manoharan, M., Sah, D.W.Y., Zamore, P.D., Aronin, N. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS https://www.ncbi.nlm.nih.gov/pubmed/17940007
  • Ghildiyal, M., Seitz, H., Horwich, M.D., Li, C., Du, T., Lee, S, Xu, J., Kittler, E.L.W., Zapp, M.L., Weng, Z., Zamore, P.D. (2008). Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells. Science 320, 1077-1081. (PMCID: PMC2953241). https://www.ncbi.nlm.nih.gov/pubmed/18403677
  • Ameres, S.L., Horwich, M.D., Hung, J., Xu, J., Ghildiyal, M., Weng, Z., Zamore, P.D. (2010). Target RNA-directed trimming and tailing of small silencing RNAs. Science 328, 1534-1539. (PMCID: PMC2902985). https://www.ncbi.nlm.nih.gov/pubmed/20558712
  • Salomon, W.E., Jolly, S.M., Moore, M.J., Zamore, P.D., Serebrov, V. (2015). Single-Molecule imaging reveals that Argonaute reshapes the binding properties of its nucleic acid guides. Cell 162, 84-95. (PMCID: PMC4503223). https://www.ncbi.nlm.nih.gov/pubmed/26140592
Phillip D. Zamore
Nationality American
Alma Mater Harvard University, Ph.D.

Harvard College, A.B.

Scientific Career
Fields Biology
Institutions University of Massachusetts Medical School

The Whitehead Institute for Biomedical Research

Skirball Institute, New York University Medical Center

Advisors Michael Green

Ruth Lehmann

Website https://www.zamorelab.umassmed.edu
  1. ^ a b c d "Phillip Zamore | Profiles RNS". profiles.umassmed.edu. Retrieved 2018-10-30.
  2. ^ a b c "Phillip D. Zamore, PhD | HHMI.org". HHMI.org. Retrieved 2018-10-30.
  3. ^ Smith, R. J.; Bryant, R. G. (1975-10-27). "Metal substitutions incarbonic anhydrase: a halide ion probe study". Biochemical and Biophysical Research Communications. 66 (4): 1281–1286. ISSN 0006-291X. PMID 3.
  4. ^ "Phillip D. Zamore - Google Scholar Citations". scholar.google.com. Retrieved 2018-10-30.
  5. ^ "Alnylam Pharmaceuticals", Wikipedia, 2018-08-11, retrieved 2018-10-30
  6. ^ "FDA approval of Alnylam drug is first ever for RNAi-based therapy - STAT". STAT. 2018-08-10. Retrieved 2018-10-30.
  7. ^ "Alnylam SAB". {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  8. ^ "Founders | Voyager Therapeutics". www.voyagertherapeutics.com. Retrieved 2018-10-30.
  9. ^ "Paper of the Year - Oligonucleotide Therapeutics Society". Oligonucleotide Therapeutics Society. Retrieved 2018-10-30.
  10. ^ "Three UMMS scientists named in 2014 Thomson Reuters Report on most influential scientific minds". University of Massachusetts Medical School. 2014-07-10. Retrieved 2018-10-30.
  11. ^ "Table 1 : Top 20 translational researchers of 2014 : Bioentrepreneur". www.nature.com. Retrieved 2018-10-30. {{cite web}}: no-break space character in |title= at position 6 (help)
  12. ^ "Search Fellows - National Academy of Inventors". academyofinventors.org. Retrieved 2018-10-30.
  13. ^ "Chancellor's Medals". University of Massachusetts Medical School. Retrieved 2018-10-30.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Phillip_D._Zamore&oldid=866500678"